New estimates of drug development costs

Journal of Health Economics

Volumn 22, Issue 2, 2003, Pages 325-330

  Frank, Richard G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; ECONOMIC ASPECT; EDITORIAL; FOOD AND DRUG ADMINISTRATION; INVESTMENT; PRESCRIPTION;

EID: 0037373590     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-6296(03)00002-X     Document Type: Editorial

References (11)

1. DiMasi, J.A., Hansen, R.W., Grabowski, H.G., 2003. The price of innovation: new estimates of drug development costs, Journal of Health Economics.
2. Food and Drug Administration (FDA), C.D.E.R., 2001. Report to the Nation: Improving Health Through Human Drugs, FDA, Rockville, MD.
3. Gluck, M., 2002. Federal Policy Affecting the Cost and Availability of New Pharmaceuticals. Kaiser Family Foundation.
4. DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of Innovation in the Pharmaceutical Industry. Journal of Health Economics. 10:1991;107-142.
5. Pharmaceutical Investment and Output. In: Proceedings of the CMR International, 2002, London.
6. PhRMA, Pharmaceutical Industry Profile 2001. Pharmaceutical Research and Manufacturers of America, Washington, DC.
7. Pindyck R. Irreversibility, Uncertainty and Investment. Journal of Economic Literature. 29(3):1991;1110-1148.
8. Public Citizen, 2002. America's Other Drug Problem: A Briefing Book on the Rx Drug Debate. Public Citizen, Washington, DC.
9. Gress, O.T.A., 1993. Pharmaceutical R&D: Costs, Risks, and Rewards. U.S. Government Printing Office, Washington, DC.
10. Walker, S., 2002. New Drugs for Old Trends in New Drug Development. In: Proceedings of the DrKW Health Care Industry Seminar, London, England.
11. Wiggins S. Product quality and regulation and new drug introductions: some new evidence from the 1970s. The Review of Economics and Statistics. 63(4):1981;615-619.